bluebird, Catalent propose $400M follow-ons

Cell therapy company bluebird bio Inc. (NASDAQ:BLUE) and drug delivery play Catalent Inc. (NYSE:CTLT) each proposed to raise $400 million follow-ons late Monday.

bluebird's follow-on will be underwritten by Goldman Sachs, BofA Merrill Lynch, J.P. Morgan, Cowen and Wells Fargo...